Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines

Genes Chromosomes and Cancer(2021)10.1002/gcc.22940Source: DataRank Database

Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines is a research paper published in Genes Chromosomes and Cancer (2021). On theSindex it has a DataRank of 0. It has been cited 23 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access23 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 2.87)OA: hybridTopics (49)Linked Datasets (10)DataCite Reuse (10)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (17)

Christopher J. Ricketts ORCID,Cathy D. Vocke ORCID,J. Keith Killian,Hesed Padilla‐Nash,Martin Lang ORCID

Live enrichment

PubMed:33527590 PMC:PMC8251606 OpenAlex:https://openalex.org/W3127289259

NCI NIH HHS

Grant: HHSN261200800001E

Intramural NIH HHS

Grant: Z01 BC011089

CCR NIH HHS

Grant: HHSN261200800001C

Intramural NIH HHS

Grant: ZIA BC011038

Intramural NIH HHS

Grant: ZIC BC011044

Intramural NIH HHS

Grant: ZIA BC011028

National Institutes of Health

Grant: 1Z01BC011089-01

Clinical Nursing and Data Management Core

FWCI

2.87

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/gcc.22940

journalhttps://doi.org/10.1002/gcc.22940

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33527590

repositoryhttps://dh.howard.edu/med_fac/96

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8251606

Fields of Study

Renal cell carcinoma treatmentRenal and related cancersCancer Genomics and Diagnostics0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

Cell Line AuthenticationAnimalsCarcinoma, Renal CellHumansKidney NeoplasmsMutationProto-Oncogene Proteins c-metCyclin-Dependent Kinase Inhibitor p16Xenograft Model Antitumor AssaysChromosomal InstabilityCell Line, TumorMice

Keywords

Papillary renal cell carcinomasCancer researchCell cultureRenal cell carcinomaClear cell renal cell carcinomaCDKN2ABiologyPathologyMedicineOncologyInternal medicineCancerGeneticsCell lineMetPapillary Renal Cell CarcinomaPrccHereditary Type 1 Papillary Renal Cell CarcinomaProto-Oncogene Proteins c-metXenograft Model Antitumor AssaysKidney NeoplasmsMiceCell Line AuthenticationCell Line, TumorChromosomal InstabilityMutationAnimalsHumansCarcinoma, Renal CellResearch ArticlesCyclin-Dependent Kinase Inhibitor p16

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma

10.6084/m9.figshare.22688633.v1figshare

Additional file 1 of High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma

10.6084/m9.figshare.22688633figshare

Additional file 3 of High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma

10.6084/m9.figshare.22688639.v1figshare

Additional file 3 of High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma

10.6084/m9.figshare.22688639figshare

Additional file 4 of High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma

10.6084/m9.figshare.22688642.v1figshare

Additional file 4 of High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma

10.6084/m9.figshare.22688642figshare

Additional file 1 of Free-fatty acid receptor-1 (FFA1/GPR40) promotes papillary RCC proliferation and tumor growth via Src/PI3K/AKT/NF-κB but suppresses migration by inhibition of EGFR, ERK1/2, STAT3 and EMT

10.6084/m9.figshare.26599516.v1figshare

10.6084/m9.figshare.26599516figshare

Additional file 2 of High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma

10.6084/m9.figshare.22688636.v1figshare

Additional file 2 of High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma

10.6084/m9.figshare.22688636figshare